{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:11:04Z","timestamp":1787317864920,"version":"build-2736575974"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003825","name":"Magyar Tudom\u00e1nyos Akad\u00e9mia","doi-asserted-by":"publisher","award":["POST-COVID2021-16"],"award-info":[{"award-number":["POST-COVID2021-16"]}],"id":[{"id":"10.13039\/501100003825","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011019","name":"Nemzeti Kutat\u00e1si Fejleszt\u00e9si \u00e9s Innov\u00e1ci\u00f3s Hivatal","doi-asserted-by":"publisher","award":["TKP2021-EGA-20 , TKP2021-EGA-19"],"award-info":[{"award-number":["TKP2021-EGA-20 , TKP2021-EGA-19"]}],"id":[{"id":"10.13039\/501100011019","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>As the COVID-19 pandemic enters its sixth year, effective vaccination strategies remain a cornerstone, particularly given the limitations in access, timing, and efficacy of currently available antiviral therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective study, we analyzed neutralizing antibody responses in serum samples from 100 vaccinated and boostered individuals using standardized cell-culture and in vitro neutralization assays. Samples were tested against the original Wuhan-Hu-1 spike protein as well as major SARS-CoV-2 variants of concern (B.1.351, B.1.617, and B.1.1.529\/Omicron). We also investigated the potential for antibody-dependent enhancement (ADE) in monocyte-derived macrophages.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Only 61% of serum samples effectively neutralized the Wuhan-Hu-1 variant; among these, 20.6% demonstrated cross-neutralization of both B.1.351 and B.1.617. Of those cross-neutralizers, 66.6% were also able to neutralize Omicron. Notably, individuals who had been both vaccinated and previously infected showed stronger neutralizing responses than those who were only vaccinated and boostered. ADE was observed in 1% of samples.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This retrospective analysis offers a valuable insight to contextualize immune responses in real-world settings, revealing how actual immunological outcomes diverged from early expectations; at least in our studied population, and underscores the importance of continuously reassessing vaccine strategies as viral evolution unfolds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1797240","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:33Z","timestamp":1775107413000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Retrospective neutralization analysis of SARS-CoV-2 variants in early pandemic sera"],"prefix":"10.3389","volume":"17","author":[{"given":"Mohamed","family":"Mahdi","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]},{"name":"Department of Infectology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aya S.","family":"Al-Muffti","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]},{"name":"Doctoral School of Molecular Cellular and Immune Biology, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tam\u00e1s Rich\u00e1rd","family":"Linkner","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]},{"name":"Doctoral School of Molecular Cellular and Immune Biology, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"No\u00e9mi","family":"Miltner","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]},{"name":"Doctoral School of Molecular Cellular and Immune Biology, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olena","family":"Mis\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Infectology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Istv\u00e1n","family":"V\u00e1rkonyi","sequence":"additional","affiliation":[{"name":"Department of Infectology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f3zsef","family":"T\u0151zs\u00e9r","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, Faculty of Medicine, University of Debrecen","place":["Debrecen, Hungary"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01911-2","article-title":"Emergence of SARS-coV-2 omicron lineages BA.4 and BA.5 in South Africa","volume":"28","author":"Tegally","year":"2022","journal-title":"Nat Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00841-7","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-022-00809-7","article-title":"SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies","volume":"21","author":"Cox","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106092","article-title":"Immune evasion of Omicron variants JN.1, KP.2, and KP.3 to the polyclonal and monoclonal antibodies from COVID-19 convalescents and vaccine recipients","volume":"235","author":"Wu","year":"2025","journal-title":"Antiviral Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-025-02030-7","article-title":"Viral evolution prediction identifies broadly neutralizing antibodies to existing and prospective SARS-CoV-2 variants","volume":"10","author":"Jian","year":"2025","journal-title":"Nat Microbiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"900","DOI":"10.3390\/v16060900","article-title":"Comprehensive overview of broadly neutralizing antibodies against SARS-CoV-2 variants","volume":"16","author":"Cui","year":"2024","journal-title":"Viruses"},{"key":"B8","unstructured":"Status of COVID-19 Vaccines within WHO EUL\/PQ evaluation process"},{"key":"B9","article-title":"COVID-19 vaccination","year":""},{"key":"B10","unstructured":"COVID-19 Vaccines (2025\u20132026 Formula) for Use in the United States Beginning in Fall 2025"},{"key":"B11","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41392-023-01391-x","article-title":"Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2","volume":"8","author":"Zhu","year":"2023","journal-title":"Signal Transduction Targeted Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(22)00390-1","article-title":"Efficacy of SARS-CoV-2 vaccines and the dose-response relationship with three major antibodies: a systematic review and meta-analysis of randomised controlled trials","volume":"4","author":"Yang","year":"2023","journal-title":"Lancet Microbe"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2022.938108","article-title":"Why does COVID-19 continue to spread despite mass vaccination","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Public Health"},{"key":"B14","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12916-022-02397-y","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis","volume":"20","author":"Zeng","year":"2022","journal-title":"BMC Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12941-023-00594-y","article-title":"The efficacy and effectiveness of COVID-19 vaccines around the world: a mini-review and meta-analysis","volume":"22","author":"Soheili","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00152-0","article-title":"Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: results of a systematic review and meta-regression","volume":"399","author":"Feikin","year":"2022","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2023.08.007","article-title":"Waning protection after vaccination and prior infection against COVID-19-related mortality over 18 months","volume":"29","author":"Dietler","year":"2023","journal-title":"Clin Microbiol Infection"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00089-7","article-title":"Risk of infection, hospitalisation, and death up to 9 months after a second dose of COVID-19 vaccine: a retrospective, total population cohort study in Sweden","volume":"399","author":"Nordstrom","year":"2022","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2025.126966","article-title":"Durability of COVID-19 vaccine and infection induced immunity: A systematic review and meta-regression analysis","volume":"54","author":"Moore","year":"2025","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2514268","article-title":"Updated evidence for covid-19, RSV, and influenza vaccines for 2025-2026","volume":"393","author":"Scott","year":"2025","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1038\/s41467-022-30162-5","article-title":"Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants","volume":"13","author":"Belik","year":"2022","journal-title":"Nat Commun"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"8743","DOI":"10.1038\/s41467-025-63711-9","article-title":"Long-persisting SARS-CoV-2 spike-specific CD4(+) T cells associated with mild disease and increased cytotoxicity post COVID-19","volume":"16","author":"Liu","year":"2025","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03653-6","article-title":"BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans","volume":"595","author":"Sahin","year":"2021","journal-title":"Nature"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn7591","article-title":"Neutralization of SARS-CoV-2 Omicron by BNT162b2 mRNA vaccine-elicited human sera","volume":"375","author":"Muik","year":"2022","journal-title":"Science"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1578733","article-title":"Progress in combination vaccines and the co-administration of influenza virus and SARS-CoV-2 vaccines","volume":"16","author":"Hu","year":"2025","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1016\/j.cell.2023.04.007","article-title":"The T-cell-directed vaccine BNT162b4 encoding conserved non-spike antigens protects animals from severe SARS-CoV-2 infection","volume":"186","author":"Arieta","year":"2023","journal-title":"Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01248-5","article-title":"The humoral response and antibodies against SARS-CoV-2 infection","volume":"23","author":"Qi","year":"2022","journal-title":"Nat Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114583","article-title":"Waning immune humoral response to BNT162b2 covid-19 vaccine over 6 months","volume":"385","author":"Levin","year":"2021","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118946","article-title":"Protection and waning of natural and hybrid immunity to SARS-CoV-2","volume":"386","author":"Goldberg","year":"2022","journal-title":"N Engl J Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 Omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B38","doi-asserted-by":"publisher","first-page":"2100563","DOI":"10.2807\/1560-7917.ES.2021.26.28.2100563","article-title":"Efficacy and effectiveness of COVID-19 vaccines against SARS-CoV-2 infection: interim results of a living systematic review, 1 January to 14 May 2021","volume":"26","author":"Harder","year":"2021","journal-title":"Euro Surveillance: Bull Europeen sur les Maladies Transmissibles = Eur Communicable Dis Bull"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1183\/16000617.0222-2024","article-title":"Effectiveness of COVID-19 vaccines against SARS-CoV-2 infection and severe outcomes in adults: a systematic review and meta-analysis of European studies published up to 22 January 2024","volume":"34","author":"Zhou","year":"2025","journal-title":"Eur Respir Review: Off J Eur Respir Soc"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1093\/immadv\/ltae011","article-title":"Systematic review and meta-analysis of COVID-19 mRNA vaccine effectiveness against hospitalizations in adults","volume":"4","author":"Wong","year":"2024","journal-title":"Immunotherapy Adv"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02219-5","article-title":"Real-world COVID-19 vaccine effectiveness against the Omicron BA.2 variant in a SARS-CoV-2 infection-naive population","volume":"29","author":"Lau","year":"2023","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1088","article-title":"Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study","volume":"373","author":"Lopez Bernal","year":"2021","journal-title":"BMJ"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1038\/s41467-024-54404-w","article-title":"Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection","volume":"15","author":"Wiegand","year":"2024","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109229118","article-title":"Asymptomatic SARS-CoV-2 infection: A systematic review and meta-analysis","volume":"118","author":"Sah","year":"2021","journal-title":"PNAS"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02015-19","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Wan","year":"2020","journal-title":"J Virol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1016\/j.cell.2020.11.031","article-title":"Unexpected receptor functional mimicry elucidates activation of coronavirus fusion","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"B51","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.1038\/s41467-020-19568-1","article-title":"Characterization of neutralizing antibody with prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus monkeys","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B52","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/s42003-022-03207-0","article-title":"Antibody-dependent enhancement (ADE) of SARS-CoV-2 pseudoviral infection requires FcgammaRIIB and virus-antibody complex with bivalent interaction","volume":"5","author":"Wang","year":"2022","journal-title":"Commun Biol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2101544","article-title":"Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19","volume":"384","author":"Sadoff","year":"2021","journal-title":"N Engl J Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00730-3","article-title":"Pandemic moves and countermoves: vaccines and viral variants","volume":"397","author":"Sanders","year":"2021","journal-title":"Lancet"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2104974","article-title":"Effectiveness of the BNT162b2 Covid-19 vaccine against the B.1.1.7 and B.1.351 variants","volume":"385","author":"Abu-Raddad","year":"2021","journal-title":"N Engl J Med"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01739-w","article-title":"Immune response to SARS-CoV-2 after a booster of mRNA-1273: an open-label phase 2 trial","volume":"28","author":"Chu","year":"2022","journal-title":"Nat Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2025.115557","article-title":"Phenotypic heterogeneity defines B cell responses to repeated SARS-CoV-2 exposures through vaccination and infection","volume":"44","author":"Kardava","year":"2025","journal-title":"Cell Rep"},{"key":"B58","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.3390\/vaccines11071196","article-title":"Booster immunization improves memory B cell responses in older adults unresponsive to primary SARS-CoV-2 immunization","volume":"11","author":"Verheul","year":"2023","journal-title":"Vaccines"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.fct.2022.113008","article-title":"Innate immune suppression by SARS-CoV-2 mRNA vaccinations: The role of G-quadruplexes, exosomes, and MicroRNAs","volume":"164","author":"Seneff","year":"2022","journal-title":"Food Chem Toxicology: Int J Published For Br Ind Biol Res Assoc"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory B cell responses in SARS-CoV-2 naive and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2015.162","article-title":"T-cell exhaustion in the tumor microenvironment","volume":"6","author":"Jiang","year":"2015","journal-title":"Cell Death Dis"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00750-4","article-title":"Activation or exhaustion of CD8(+) T cells in patients with COVID-19","volume":"18","author":"Rha","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2021.644574","article-title":"No evidence for human monocyte-derived macrophage infection and antibody-mediated enhancement of SARS-CoV-2 infection","volume":"11","author":"Garcia-Nicolas","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01553-21","article-title":"Multiple routes of antibody-dependent enhancement of SARS-CoV-2 infection","volume":"10","author":"Okuya","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199708000-00002","article-title":"Two parallel routes of the complement-mediated antibody-dependent enhancement of HIV-1 infection","volume":"11","author":"Prohaszka","year":"1997","journal-title":"Aids"},{"key":"B66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s41745-021-00268-8","article-title":"Neutralizing antibodies and antibody-dependent enhancement in COVID-19: A perspective","author":"Ajmeriya","year":"2022","journal-title":"J Indian Inst Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/science.1260419","article-title":"Proteomics. Tissue-based map of the human proteome","volume":"347","author":"Uhlen","year":"2015","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/infdis\/jiab044","article-title":"Monocytes and macrophages, targets of severe acute respiratory syndrome coronavirus 2: The clue for coronavirus disease 2019 immunoparalysis","volume":"224","author":"Boumaza","year":"2021","journal-title":"J Infect Dis"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682871","article-title":"The role of macrophages in the pathogenesis of SARS-CoV-2-associated acute respiratory distress syndrome","volume":"12","author":"Kosyreva","year":"2021","journal-title":"Front Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1055429","article-title":"Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing","volume":"14","author":"O'Shea","year":"2023","journal-title":"Front Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797240\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T05:23:35Z","timestamp":1775107415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1797240\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1797240"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1797240","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"article-number":"1797240"}}